Journal article
The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes
A Quinlivan, D Neuen, D Hansen, W Stevens, L Ross, N Ferdowsi, SM Proudman, JG Walker, J Sahhar, G-S Ngian, D Apostolopoulos, LV Host, G Major, C Basnayake, K Morrisroe, M Nikpour
Arthritis Research & Therapy | BMC | Published : 2024
Abstract
Background: To determine the relationship between gastroesophageal reflux disease (GORD) and its treatment and interstitial lung disease in patients with systemic sclerosis (SSc). Methods: SSc patients from the Australian Scleroderma Cohort Study (ASCS) were included. GORD was defined as self-reported GORD symptoms, therapy with a proton pump inhibitor (PPI) or histamine 2 receptor antagonist (H2RA) and/or the presence of reflux oesophagitis diagnosed endoscopically. The impact of GORD and its treatment on ILD features (including severity and time to ILD development) and survival was evaluated. Results: GORD was a common manifestation affecting 1539/1632 (94%) of SSc patients. GORD affected ..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia Investigator Grant
Funding Acknowledgements
Not applicable.